Skip to content
DraconiticResearch
Search Sources API
203,234 studies31 sourcesUpdated 53 min ago
Peer-reviewedCC BY 4.0International Journal of Clinical Oncology

Tarlatamab in small cell lung cancer following platinum-based chemotherapy: subgroup analysis of Japanese patients from the DeLLphi-304 study

  • Takayasu Kurata1
  • Shunichi Sugawara2
  • Hiroaki Akamatsu3
  • Kazushige Wakuda4
  • Koichi Azuma5
  • Takayuki Takahama6
  • Hiroshi Kagamu7
  • Hiroshi Yokouchi8
  • Miyako Satouchi9
  • Shuji Murakami10
  • Kadoaki Ohashi11
  • Makoto Nishio12
8 more authors
  • Kazumi Nishino13
  • Hiroki Izumi14
  • Hiroshi Tanaka15
  • Taichi Miyawaki16
  • Shuang Huang17
  • Upen Patil17
  • Jihyun Park18
  • Tatsuya Yoshida19
19 affiliations
  1. 1Department of Thoracic Oncology, Kansai Medical University Hospital, 2-3-1 Shin-machi, Hirakata city, Osaka 573-1191 Japan
  2. 2Sendai Kousei Hospital, Miyagi, Japan
  3. 3Internal Medicine III, Wakayama Medical University Hospital, Wakayama, Japan
  4. 4Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan
  5. 5Division of Respirology, Neurology, and Rheumatology, Department of Internal Medicine, Kurume University School of Medicine, Fukuoka, Japan
  6. 6Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka-Sayama, Japan
  7. 7Department of Respiratory Medicine, International Medical Center, Saitama Medical University, Saitama, Japan
  8. 8Department of Respiratory Medicine, NHO Hokkaido Cancer Center, Sapporo, Japan
  9. 9Department of Thoracic Oncology, Hyogo Cancer Center, Akashi, Japan
  10. 10Department of Thoracic Oncology, Kanagawa Prefectural Hospital Organization Kanagawa Cancer Center, Yokohama, Japan
  11. 11Department of Respiratory Medicine, Okayama University Hospital, Okayama, Japan
  12. 12Department of Thoracic Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan
  13. 13Department of Thoracic Oncology, Osaka International Cancer Institute, Osaka, Japan
  14. 14Department of Thoracic Oncology, National Cancer Center Hospital East, Chiba, Japan
  15. 15Department of Internal Medicine, Niigata Cancer Center Hospital, Niigata, Japan
  16. 16Department of Respiratory Medicine, Graduate School of Medicine, Juntendo University, Tokyo, Japan
  17. 17Amgen Inc, Thousand Oaks, CA USA
  18. 18Amgen K.K, Tokyo, Japan
  19. 19Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan
Read full textPDFDOICite

Abstract

Background: In the Phase 3 DeLLphi-304 trial, tarlatamab significantly improved overall survival (OS) over chemotherapy for small-cell lung cancer (SCLC) progressed after platinum-based chemotherapy. We report efficacy and safety in the Japanese subpopulation.

Methods: Patients were randomized to tarlatamab or amrubicin in Japan. The primary endpoint was OS. Secondary endpoints included progression-free survival (PFS), objective response rate (ORR), duration of response (DOR), and safety.

Results: As of 29 Jan 2025 (data cutoff), 35 patients (tarlatamab, n = 12; amrubicin, n = 23) were enrolled. Baseline characteristics were generally balanced although fewer tarlatamab-treated patients had chemotherapy-free interval < 90 days or brain metastases. Median OS was NE (95% CI, 10.4, NE) for tarlatamab versus 11.5 (6.2, NE) months for amrubicin (HR [95% CI] = 0.533 [0.186, 1.529]). Twelve-month survival was 66.7% (33.7, 86.0) versus 47.0% (25.7, 65.6), respectively. Median PFS was 4.0 (1.3, 11.3) months versus 4.2 (2.1, 5.4) months (HR [95% CI] = 0.726 [0.339, 1.554]). ORR was 33.3% (9.9, 65.1) versus 26.1% (10.2, 48.4). Median DOR was 10.1 (3.0, NE) months versus 5.6 (2.8, NE) months. Grade ≥ 3 treatment-related adverse events were less frequent with tarlatamab (8.3%) versus amrubicin (56.5%). Cytokine release syndrome occurred in 75% of tarlatamab-treated patients (all were grade 1 or 2) and grade 2 immune effector cell-associated neurotoxicity syndrome was reported in 1 (8.3%) patient.

Conclusion: Tarlatamab demonstrated numerically longer OS and DOR, and higher ORR versus amrubicin in Japanese patients with SCLC, with fewer high-grade treatment-related adverse events. These results in Japanese patients support those of the global population.

Supplementary Information: The online version contains supplementary material available at https://doi.org/10.1007/s10147-026-03192-y.

Related

  1. Extended follow-up of tarlatamab in patients with small-cell lung cancer after platinum-based chemotherapy in the randomized phase 3 DeLLphi-304 study
    C.M. Rudin, M-J. Ahn, M. Schuler +17
    Annals of oncology : official journal of the European Society for Medical OncologyPeer-reviewedCC BYFull textOncologyPMC
  2. Guillain-Barré Syndrome Following the Administration of Tarlatamab in Extensive-stage Small Cell Lung Cancer: A Case Report with Pathological Confirmation
    Yoshihisa Tokunaga, Koichi Azuma, Kenichi Irie +6
    Internal MedicinePeer-reviewedCC BY-NC-NDFull text1 citedNeurologyJ-STAGE
  3. Case Report: Apparent progressive complete mismatch repair protein loss during platinum-based chemotherapy in metastatic rectal neuroendocrine tumour grade 2
    Yue Yang, Gao Li, Jinghui Wang +2
    Frontiers in oncologyPeer-reviewedCC BYFull textOncologyEurope PMC
  4. Homoharringtonine targets XPC to inhibit DNA damage repair and sensitize tumors to platinum-based chemotherapy
    C. Wang, Y. Zhang, X. Zhou +8
    bioRxivPreprintAll rights reservedFull textPharmacology & toxicologybioRxiv
  5. Amivantamab plus chemotherapy vs. chemotherapy in participants with EGFR-mutant advanced non-small cell lung cancer after progression on osimertinib: a MARIPOSA-2 analysis of the Asian subgroup
    Jin-Yuan Shih, Jie Wang, Yongsheng Wang +15
    Translational Lung Cancer ResearchPeer-reviewedCC BY-NC-NDFull textOncologyEurope PMC

Cite

BibTeXRIS
BibTeX
@article{kurata2026tarlatamab,
  title = {{Tarlatamab in small cell lung cancer following platinum-based chemotherapy: subgroup analysis of Japanese patients from the DeLLphi-304 study}},
  author = {Takayasu Kurata and Shunichi Sugawara and Hiroaki Akamatsu and Kazushige Wakuda and Koichi Azuma and Takayuki Takahama and Hiroshi Kagamu and Hiroshi Yokouchi and Miyako Satouchi and Shuji Murakami and Kadoaki Ohashi and Makoto Nishio and Kazumi Nishino and Hiroki Izumi and Hiroshi Tanaka and Taichi Miyawaki and Shuang Huang and Upen Patil and Jihyun Park and Tatsuya Yoshida},
  journal = {International Journal of Clinical Oncology},
  year = {2026},
  month = sep,
  doi = {10.1007/s10147-026-03192-y},
  url = {https://doi.org/10.1007/s10147-026-03192-y},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - Tarlatamab in small cell lung cancer following platinum-based chemotherapy: subgroup analysis of Japanese patients from the DeLLphi-304 study
AU  - Takayasu Kurata
AU  - Shunichi Sugawara
AU  - Hiroaki Akamatsu
AU  - Kazushige Wakuda
AU  - Koichi Azuma
AU  - Takayuki Takahama
AU  - Hiroshi Kagamu
AU  - Hiroshi Yokouchi
AU  - Miyako Satouchi
AU  - Shuji Murakami
AU  - Kadoaki Ohashi
AU  - Makoto Nishio
AU  - Kazumi Nishino
AU  - Hiroki Izumi
AU  - Hiroshi Tanaka
AU  - Taichi Miyawaki
AU  - Shuang Huang
AU  - Upen Patil
AU  - Jihyun Park
AU  - Tatsuya Yoshida
PY  - 2026
DA  - 2026/09/19
JO  - International Journal of Clinical Oncology
DO  - 10.1007/s10147-026-03192-y
UR  - https://doi.org/10.1007/s10147-026-03192-y
AB  - Background: In the Phase 3 DeLLphi-304 trial, tarlatamab significantly improved overall survival (OS) over chemotherapy for small-cell lung cancer (SCLC) progressed after platinum-based chemotherapy. We report efficacy and safety in the Japanese subpopulation.  Methods: Patients were randomized to tarlatamab or amrubicin in Japan. The primary endpoint was OS. Secondary endpoints included progression-free survival (PFS), objective response rate (ORR), duration of response (DOR), and safety.  Results: As of 29 Jan 2025 (data cutoff), 35 patients (tarlatamab, n = 12; amrubicin, n = 23) were enrolled. Baseline characteristics were generally balanced although fewer tarlatamab-treated patients had chemotherapy-free interval < 90 days or brain metastases. Median OS was NE (95% CI, 10.4, NE) for tarlatamab versus 11.5 (6.2, NE) months for amrubicin (HR [95% CI] = 0.533 [0.186, 1.529]). Twelve-month survival was 66.7% (33.7, 86.0) versus 47.0% (25.7, 65.6), respectively. Median PFS was 4.0 (1.3, 11.3) months versus 4.2 (2.1, 5.4) months (HR [95% CI] = 0.726 [0.339, 1.554]). ORR was 33.3% (9.9, 65.1) versus 26.1% (10.2, 48.4). Median DOR was 10.1 (3.0, NE) months versus 5.6 (2.8, NE) months. Grade ≥ 3 treatment-related adverse events were less frequent with tarlatamab (8.3%) versus amrubicin (56.5%). Cytokine release syndrome occurred in 75% of tarlatamab-treated patients (all were grade 1 or 2) and grade 2 immune effector cell-associated neurotoxicity syndrome was reported in 1 (8.3%) patient.  Conclusion: Tarlatamab demonstrated numerically longer OS and DOR, and higher ORR versus amrubicin in Japanese patients with SCLC, with fewer high-grade treatment-related adverse events. These results in Japanese patients support those of the global population.  Supplementary Information: The online version contains supplementary material available at https://doi.org/10.1007/s10147-026-03192-y.
SN  - 1341-9625
SN  - 1437-7772
ER  -